Press release
Gout Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Gout Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Gout Pipeline Outlook Report [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Gout Pipeline Report
* In June 2025, Arthrosi Therapeutics announced a study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months.
* DelveInsight's Gout pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Gout treatment.
* The leading Gout Companies such as Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
* Promising Gout Pipeline Therapies such as Pegloticase, Methotrexate, Epaminurad 6 mg, ABP-671, Allopurinol, D-0120, Dotinurad, Febuxostat and others.
Discover how the Gout treatment paradigm is evolving. Access DelveInsight's in-depth Gout Pipeline Analysis for a closer look at promising breakthroughs @ Gout Clinical Trials and Studies [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Gout Emerging Drugs Profile
* LC350189: LG Chem
Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase. It has a different structure from other xanthine oxidase inhibitors such as the purine analog xanthine oxidase inhibitor, allopurinol. Tigulixostat is under development as a first line treatment in the US and has demonstrated sufficient efficacy for sUA lowering and a good safety profile in a Phase II study. Currently, the drug is in the Phase III stage of its development for the treatment of Gout.
* SAP-001: Shanton Pharma
SAP-001 is an investigational drug developed by Shanton Pharma, specifically designed to treat refractory and tophaceous gout, a severe form of the condition that often does not respond to standard treatments. This drug functions as a urate transporter inhibitor, targeting the uric acid transporter 1 (URAT1) to lower urate levels in patients who have not adequately responded to traditional therapies like allopurinol or febuxostat. Currently, the drug is in the Phase II stage of its development for the treatment of Gout.
* D-0120: InventisBio
D-0120 is a novel oral selective uric acid transporter (URAT1) inhibitor being developed for the treatment of gout by blocking the reabsorption of uric acid (UA) within the renal proximal tubule, thereby reducing serum uric acid concentrations. As a novel URAT1 inhibitor, D-0120 is anticipated to have more potent serum UA reducing effect than the approved URAT1 inhibitor lesinurad, but with less toxicity and wider therapeutic window. The pharmacological potential of D-0120 for the treatment of hyperuricemia and gout was demonstrated in preclinical studies. The results of the in vitro hURAT1 expressed CHO cell model showed that the inhibitory activity of D-0120 is 150-fold more potent than lesinurad and slightly more potent than verinurad. A Phase I clinical trial for D-0120 has been completed in the US, and good efficacy and excellent safety profile have been observed. Currently, the drug is in the Phase II stage of its development for the treatment of Gout.
* ABP-745: Jiangsu Atom Bioscience and Pharmaceutical
ABP-745 is an emerging small molecule drug developed by Atom Bioscience, primarily targeting the treatment of acute gout. While specific mechanisms are not fully detailed, ABP-745 is noted for its anti-inflammatory properties and is designed to be orally administered. According to the company's pipeline, currently the drug is in the Phase II stage of its development for the treatment of Gout.
The Gout Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
* Gout Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market
Explore groundbreaking therapies and clinical trials in the Gout Pipeline. Access DelveInsight's detailed report now! @ New Gout Drugs [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Gout Companies
Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
Gout Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
Gout Products have been categorized under various Molecule types such as
* Protein
* Small interfering RNA
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Gout Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Gout Pipeline Report
* Coverage- Global
* Gout Companies- Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova Pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, Shenyang Sunshine Pharmaceutical and others.
* Gout Pipeline Therapies- Pegloticase, Methotrexate, Epaminurad 6 mg, ABP-671, Allopurinol, D-0120, Dotinurad, Febuxostat and others.
* Gout Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Gout Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Gout drug development? Find out in DelveInsight's exclusive Gout Pipeline Report-access it now! @ Gout Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Gout: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Gout- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* LC350189: LG Chem
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SAP-001: Shanton Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Gout Key Companies
* Gout Key Products
* Gout- Unmet Needs
* Gout- Market Drivers and Barriers
* Gout- Future Perspectives and Conclusion
* Gout Analyst Views
* Gout Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gout-pipeline-appears-robust-with-25-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gout Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4082134 • Views: …
More Releases from ABNewswire
Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Com …
DelveInsight's, "Clostridium Difficile Infections Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Clostridium Difficile Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive…
Orthopedic Power Tools Market Growing at 4.15% CAGR, to Reach USD 2.17 Billion b …
Mordor Intelligence has published a new report on the Orthopedic Power Tools market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
Mordor Intelligence, in its latest Orthopedic Power Tools Market report, forecasts the market to grow from USD 1.77billion in 2025 to USD 2.17billion by 2030, at a CAGR of 4.15%. The orthopedic power tools market [https://www.mordorintelligence.com/industry-reports/orthopedic-power-tools-market?utm_source=abnewswire] refers to the segment of medical devices specifically designed for…
Closed System Transfer Devices Market to Reach USD2.67Billion by 2030 at 13.2% C …
Mordor Intelligence has published a new report on the Closed System Transfer Devices Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
According to a 2025 report by Mordor Intelligence, the Closed System Transfer Devices market size is projected to grow from USD1.43billion in2025 to USD2.67billion by2030, registering a CAGR of 13.20% over the forecast period. The Closed System Transfer Devices (CSTD) market [https://www.mordorintelligence.com/industry-reports/closed-system-transfer-devices-market?utm_source=abnewswire] plays a crucial…
Wastewater Treatment Services Market Industry Analysis by Size, Share, Growth, S …
The Wastewater Treatment Services industry is witnessing steady growth driven by rising industrialization, urban population expansion, and stricter environmental regulations. As water scarcity becomes a global concern, industries and municipalities are increasingly investing in advanced treatment solutions. The market is expected to expand further with innovations in membrane technology, biological treatment, and sustainable practices enhancing service efficiency and compliance.
The global wastewater treatment services market is projected to grow from USD…
More Releases for Gout
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
Gout Therapeutics Market - Growth Management 2017-2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Request Sample Copy of the Report @
https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2549
Patients with multiple episodes of…
Gout Therapeutics Market Moderately consolidated by 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
Gout Therapeutics Market - Future Growth & Forecast 2017-2025
Global Gout Therapeutics Market: Overview
Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries. But in the recent times, especially in the U.S., the prevalence of gout has increased to greater extents, which is a reflection of growing population with obesity, smoking habits, and increased intake of alcohol. Increased level of uric acid in the…
Gout Therapeutics - Emerging Markets in Developing Countries
Qyresearchreports include new market research report Gout Therapeutics to its huge collection of research reports.
The global market for Gout Therapeutics is discussed in detail within a new research study added recently to QYResearchReports.com. The report has been carefully examined both qualitatively and quantitatively and the results are revealed in the research report for the forecast period of 2017 to 2022. In addition to this, the various drivers and restraints, regulatory…
